Printer Friendly Version View printer-friendly version
<< Back

Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings

SAN DIEGO--(BUSINESS WIRE)--Apr. 17, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel echinocandin antifungal CD101 and its CloudbreakTM antibacterial immunotherapy CD201 will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria from April 22-25 and at the 2017 Society for Investigative Dermatology (SID) Annual Meeting in Portland, Oregon from April 26-29.

“These presentations highlight the potential of our CD101 and Cloudbreak platforms to address the unmet need for new therapeutic approaches to treat and prevent fungal and bacterial infections -- particularly those that are resistant to existing anti-infectives,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “These research findings reinforce our commitment to investigate the full clinical utility of our novel anti-infective product candidates across a range of formulations and indications.”

A total of five presentations, comprising one oral presentation and four posters, will highlight data evaluating the potential of Cidara’s lead drug candidates, CD101 and CD201, to treat and prevent serious infections. The ECCMID presentations include data on CD101 in Candida auris, an emerging virulent fungal infection, as well the compound’s potential for use as a subcutaneous formulation for prophylactic treatment in candidiasis and aspergillosis. Data from studies related to the antibacterial activity of CD201 in Gram-negative bacterial infections will also be presented at ECCMID. Finally, the SID presentation will include data on the efficacy of CD101 as a potential treatment for dermatophytosis and onychomycosis, fungal infections of the skin and nails.

Details of the Cidara ECCMID and SID 2017 presentations are as follows:

ECCMID 2017 Presentations

 

Oral Presentation:

 

Title: In-vitro characterization of antibacterial activity, cidality and spontaneous resistance potential of CD201,
a novel lipopolysaccharide-binding antibacterial immunotherapy; J. Locke, et. al. (Abstract 6210)

 

Date and time: Monday, April 24 from 10:24 a.m. – 10:34 a.m. Central European Daylight Time (CEDT)

 

Location: Reed Messe Wien, Hall K

 

Presentation number: OS0566

 

Session: New drugs against Gram-negatives: from discovery to late-stage development

 

Poster Presentations:

 

Title: Susceptibility of recent Candida auris isolates to the novel echinocandin CD101 and comparator
antifungal agents; M.A. Ghannoum, et. al. (Abstract 9037)

 

Date and Time: Saturday, April 22 from 8:45 a.m. – 3:30 p.m. CEDT

 

Location: Reed Messe Wien, ePoster Viewing Area

 

Presentation number: EV0128

 

Session: Fungal infection & disease

 

Title: Antibacterial activity of CD201, a novel lipopolysaccharide-binding antibacterial immunotherapy,
against recent Gram-negative clinical isolates, including colistin-resistant strains; J. Locke, et. al. (Abstract 7345)

 

Date and time: Saturday, April 22 from 3:30 p.m. – 4:30 p.m. CEDT

 

Location: Reed Messe Wien, Paper Poster Area

 

Presentation number: P0475

 

Session: New antibody and immunomodulatory approaches

 

Title: Prophylactic, single-dose, subcutaneous (SC) administration of CD101 shows robust efficacy
in neutropenic mouse models of candidiasis and aspergillosis; V. Ong, et. al. (Abstract 3008)

 

Date and time: Monday, April 24 from 1:30 p.m. – 2:30 p.m. with ePoster Discussion from 2:06 p.m. – 2:11 p.m. CEDT

 

Location: Reed Messe Wien, ePoster Arena 5

 

Presentation number: EP0703

 

Session: Candida infections: from changing epidemiology to changing treatment

 

All ECCMID abstracts are available on the conference website at www.eccmidlive.org.

SID 2017 Poster Presentation

 

Title: Efficacy of CD101, a novel echinocandin, in the treatment of dermatophytosis
using a guinea pig (GP) model; C.L. Hager, et. al.

 

Date and time: Friday, April 28 from 12:00 p.m. – 1:00 p.m. Pacific Daylight Time

 

Location: Oregon Convention Center, Exhibit Hall A Foyer

 

Abstract number: 689

 

Session: Selected ePoster Discussion II – Pharmacology and drug development

 

Copies of these presentations and posters will be available on the Cidara website following the meetings: http://www.Cidara.com/

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara recently received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, and other attributes of CD101 and CD201 and other potential product candidates, including the potential for these compounds to successfully treat fungal or bacterial infections, including those caused by resistant pathogens, and potentially transform the way infectious diseases are treated, and the potential for the Cloudbreak platform to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Source: Cidara Therapeutics, Inc.

Cidara Therapeutics
INVESTORS
Westwicke Partners, LLC
Robert H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com